Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Status: Recruiting
Location: See location...
Intervention Type: Procedure, Other, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye
Locations
United States
Alabama
Glaukos Investigative Site
RECRUITING
Dothan
Contact Information
Primary
Study Director
ClinicalResearch@glaukos.com
949-739-8749
Time Frame
Start Date: 2026-02-17
Estimated Completion Date: 2032-03
Participants
Target number of participants: 510
Treatments
Experimental: Cohort X Gen 2 Travoprost Intracameral Implant Arm
Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 12 and be followed for an additional 12 months
Active_comparator: Cohort X Timolol Arm
Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will administer timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo a sham exchange procedure at month 12 and be followed for an additional 12 months
Active_comparator: Cohort Y Gen 2 Travoprost Intracameral Implant Arm
Randomized, double-masked, active-controlled, Phase 3 portion of the trial, subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 24 and be followed for an additional 12 months
Active_comparator: Cohort Y Timolol Arm
Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will receive timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo a sham exchange procedure at month 24 and be followed for an additional 12 months
Experimental: Cohort Z Gen 2 Travoprost Intracameral Implant Arm
Randomized, double-masked, active-controlled, Phase 3 portion of the trial, subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 36 and be followed for an additional 12 months
Active_comparator: Cohort Z Timolol Arm
Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will administer timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo an sham exchange procedure at month 36 and be followed for an additional 12 months
Related Therapeutic Areas
Sponsors
Leads: Glaukos Corporation